Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.
Saved in:
| Title: | Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. |
|---|---|
| Authors: | Catlett, Ian M.1 (AUTHOR), Gao, Lu1 (AUTHOR) Lu.Gao@bms.com, Hu, Yanhua1 (AUTHOR), Banerjee, Subhashis1 (AUTHOR), Krueger, James G.2 (AUTHOR) |
| Source: | Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2827-2839. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
